NMO characterized by involvement of optic nerve and spinal cord [
7]. The pathogenesis of NMO is mediated by the humoral immune system in contrast to the cellular mechanism that is proposed for MS, NMO-IgG (anti-AQP4) play a direct role in the pathogenesis of NMO. Aquaporin-4 (AQP4), is a water channel protein highly concentrated in spinal cord gray matter surrounding the central canal, periaqueductal and Virchow-robin space in the periventricular regions, and astrocytic foot processes at the blood-brain barrier [
8]. The patient that seropositive for this antibody, are at risk of relapse but in general the recurrence rate in patient with longitudinal extensive transverse myelitis (LETM) is uncertain and continue to be a subject of case reports [
9]. Our patient also has the recurrent severe myelitis during 2 months that is unusual. Furthermore, the median age for presentation of NMO is 32 - 42 years, although cases present in older and young population, but the presentation at this age usually uncommon and until this time, our case is the oldest reported case in Iran. The CSF has pleocytosis in 80% - 85% patients of Devic disease although in our case was normal. Another interesting point in our patient is sudden onset of respiratory arrest without evidence of pneumonia or pulmonary embolism that may be due to upper cervical or medullary involvement in the acute phase. The plasma exchange recommended for moderate to severe transverse myelitis and optic neuritis and if refractory to prednisolone and plasma exchange , immunosuppression with cyclophosphamide recommended and due to high risk of recurrence, maintenance therapy with Azathioprine, rituximab, mycophenolate mofetil, methotrexate, prednisone, or mitoxantrone should be considered and at first Azathioprine and prednisone was prescribed that if don’t respond to this drug it is necessary to change to other drugs [
10]. Recently, many studies suggest that the therapeutic option in NMO should be immunosuppressive rather than immunomodulatory drugs [
11]. In study Mok and his colleagues showed that use of cyclophosphamide was successful in halting relapses in a patient with systemic lupus erythematosus-associated NMO who was unresponsive to high-dose oral and intravenous corticosteroids, intravenous immunoglobulin, mycophenolate mofetil, tacrolimus, low-dose daily oral cyclophosphamide and rituximab [
12]. Unfortunately our case doesn’t respond to treatment and during plasma exchange was expired.